RedHill Biopharma announced that it received confirmation from The Nasdaq Stock Market that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on December 8, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDHL:
- RedHill Biopharma announces new non-dilutive external funding
- Biotech Alert: Searches spiking for these stocks today
- RedHill Biopharma announces FDA grant of 5-year market exclusivity for Talicia
- RedHill Biopharma to transfer listing to Nasdaq Capital Market
- RedHill Biopharma files to sell 8.86M American Depositary Shares for holders